ERBB2 and non-small cell lung carcinoma: The subsequent phase II DESTINY-Lung02 trial revealed that for HER2-mutant, pre-treated NSCLC patients, a 5.4 mg/kg Q3W dosage of T-DXd outperforms the 6.4 mg/kg Q3W regimen, achieving higher ORR (53.8% vs. 42.9%), with reduced severe TRAEs (31.7% vs. 58%) and ILD incidence (5.9% vs. 14%) [56].